Inclusion Criteria:

- Histologically confirmed metastatic colorectal cancer

- ECOG performance status 0-2

- Mesurable lesions

- No prior chemotherapyk or radiotherapy for metastatic disease. Prior radiotherapy is
permitted if it was not administered to target lesions selected for this study and
provided it has been completed at least 4 weeks before registration

- Adjuvnat chemo or radiotherapy was completed at least 6 months prior to start study
treatment

- Adequate organ functions

- Expected survival is longer then 6 months

- Informed consent

Exclusion Criteria:

- Prior systemic chemotherapy for metastatic disease

- Prior treatment with oxaliplatin or irinotecan

- CNS metastases

- Uncontrolled or severe cardiovascular disease

- Serious concurrent infection or nonmalignant illness that is uncontrolled or whose
control may be jeopardized by complications of study therapy

- Other malignancy within the past 3 years except cured non-melanomatous skin cancer or
carcinoma in situ of the cervix

- Psychiatric disorder or uncontrolled seizure that would preclude compliance

- Pregnant, nursing women or patients with reproductive potential without contraception

- Patients receiving a concomitant treatment with drugs interacting with capecitabine
such as flucytosine, phenytoin, or warfarin et al.

- Prior unanticipated severe reaction to fluoropyrimidine therapy, or known
dihydropyrimidine dehydrogenase (DPD) deficiency

- Major surgery within 3 weeks prior to study treatment starts, or lack of complete
recovery from the effects of major surgery